Anti-myelin antibodies in multiple sclerosis: clinically useful?
Open Access
- 1 June 2006
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 77 (6) , 712
- https://doi.org/10.1136/jnnp.2006.089839
Abstract
Anti‐myelin antibodies may have predictive clinical value, but striking correlations as reported earlier are unlikelyKeywords
This publication has 6 references indexed in Scilit:
- Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating eventJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosisMultiple Sclerosis Journal, 2005
- Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjectsNeurology, 2004
- Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.International Immunology, 2004
- Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating EventNew England Journal of Medicine, 2003